VSCO Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Loading...
VSCO is not a good buy right now for an impatient buyer. Price action is still bearish (negative/expanding MACD and a break below the first support zone), and probabilistic trend data also leans negative over the next month. While the stock looks short-term oversold and Wall Street targets skew higher, the tape and momentum do not yet confirm a durable turn.
VSCO closed at 54.70 (-2.66% on the day), sitting below S1 (55.37) and above S2 (52.63), which puts it in a near-support zone but not yet showing confirmed strength. Momentum is bearish: MACD histogram is -1.389 and negatively expanding (downtrend pressure increasing). RSI(6) at ~27.1 indicates oversold conditions (near-term bounce risk), but oversold alone is not a buy trigger without reversal confirmation. Moving averages are converging, suggesting the prior trend may be slowing, but not yet flipped upward. Key levels: reclaiming 55.37 (S1) would be the first step toward stabilization; failure risks a move toward ~52.63 (S2).
and gross margin improvement (+5.01% YoY to 36.48%), which supports the bull case that operational levers are working. Options open-interest skew is call-favorable (OI P/C 0.61), implying investors are still positioning for upside.
Near-term technical momentum is still bearish (MACD negative and worsening; price below S1). The stock-pattern probability set also points to a negative next-month bias (-4.89%). Profitability remains weak: 2026/Q3 net income was -$37M and EPS was -0.46 (both worse YoY), which can cap upside if investors refocus on earnings quality. No recent news catalysts were provided to interrupt the current down-momentum. No supportive insider/congress buying signals were provided (insiders/hedge funds flagged as Neutral; no congress trades reported).
2026/Q3: Revenue increased to $1.472B (+9.28% YoY), showing top-line momentum. Gross margin improved to 36.48% (+5.01% YoY), a clear operational positive. However, profitability deteriorated: Net income fell to -$37M (-33.93% YoY) and EPS dropped to -0.46 (-35.21% YoY). Overall: improving sales and margins, but the company is still not translating that into bottom-line profits yet.
Recent analyst trend is upward: Barclays (Overweight) raised PT to $65; Jefferies (Buy) raised PT to $65; Telsey upgraded to Outperform with a $66 PT; Wells Fargo upgraded to Equal Weight but with a lower $45 PT; Goldman remains Neutral and most recently raised PT to $53 (now slightly below the current price). Wall Street pros: improving brand/product momentum, PINK traction, and margin expansion potential. Wall Street cons: mixed conviction (several Neutrals/Equal Weight), and some targets below the current price (e.g., Goldman $53, Wells $45), reflecting uncertainty around sustained demand and earnings power.
